Navigation Links
Resident physicians seldom trained in skin cancer examination

Many resident physicians are not trained in skin cancer examinations, nor have they ever observed or practiced the procedure, according to a report in the October issue of Archives of Dermatology, one of the JAMA/Archives journals.

Melanoma is the only cancer that can be detected early for which U.S. death rates are not decreasing, according to background information in the article. Although melanoma remains the second most common cause of cancer in individuals age 15 to 29, screening rates have not changed in recent years. "In response, a number of recommendations have been made to provide training programs for instruction of the skin cancer examination," the authors write. About one-fourth of all melanomas are detected by physicians as opposed to patients, and a consensus is emerging that cancers detected by a clinician are generally thinner and have a better prognosis. However, most primary care physicians do not regularly perform skin examinations.

Emily Wise, M.D., of the Boston University School of Medicine, and colleagues surveyed resident physicians in family medicine, obstetrics and gynecology, pediatrics and internal medicine in November 2003. Residents reported their training and experience with skin cancer examinations, along with their current skill level in performing the exams.

Of 454 surveys distributed, 342 residents in four programs completed the survey (a 75.3 percent response rate). "Clinical training for the skin cancer examination during residency was infrequent," the authors write. "During residency, 75.8 percent were never trained in the skin cancer examination, 55.3 percent never observed a skin cancer examination and 57.4 percent never practiced the examination. Only 15.9 percent of residents reported being skilled in the skin cancer examination."

Performing four skin cancer examinationsan average of slightly more than one per year of residencywas associated with increases in self-reported skill levels.

"Visits to internists and family practitioners make up an estimated 40 percent of physician visits in the United States, and nearly two-thirds of patients with melanoma report a physician visit in the year before diagnosis. Primary care physicians are thus ideally suited to screen and triage high-risk patients and those with suspicious lesions," the authors write.

"Residency programs and medical schools may have neither the time nor the infrastructure to teach an expert, comprehensive examination to all physicians in training," they conclude. "However, the basic ability to recognize potentially suspicious lesions and triage persons with such lesions should be a vital and key component of both training programs. If current physicians in training do not learn this skill set in medical school or residency, there is a low likelihood that they will acquire this knowledge in their day-to-day practice, which could have potentially devastating consequences for melanoma recognition going forward."


Contact: Todd Datz
JAMA and Archives Journals

Related medicine news :

1. S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President
2. MassMutual Promotes Debra Palermino to Senior Vice President of Human Resources
3. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Limiting Residents Hours Has Little Impact on Patient Mortality
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
8. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
9. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
10. Resonant Medical Appoints New Vice President of Global Sales
11. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
Post Your Comments:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: